


Cell Metabolism

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells

Graphical Abstract



Authors

Brian J. Altman, Annie L. Hsieh, Arjun Sengupta, ..., John B. Hogenesch, Aalim M. Weljie, Chi V. Dang

Correspondence

dangvchi@exchange.upenn.edu

In Brief

Altman et al. show that oncogenic MYC disrupts the molecular clock and alters circadian glucose metabolism and glutaminolysis in favor of growth-related biosynthesis in cancer cells. Both MYC and N-MYC upregulate REV-ERB α , which suppresses BMAL1 expression and oscillations. High REV-ERB α or low BMAL1 predicts poor clinical outcome in N-MYC-driven human neuroblastomas.

Highlights

- The *MYC* and *MYCN* oncogenes disrupt the circadian molecular clock
- MYC directly activates negative regulators of BMAL1-CLOCK
- Constitutive activation of negative regulators, REV-ERBs, suspends the clock
- Clock suspension is associated with disruption of circadian metabolic oscillation



MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells

Brian J. Altman,^{1,2,17} Annie L. Hsieh,^{1,2,10,17} Arjun Sengupta,³ Saikumari Y. Krishnanaiah,³ Zachary E. Stine,^{1,2} Zandra E. Walton,^{1,2} Arvin M. Gouw,^{1,2} Anand Venkataraman,^{4,5} Bo Li,^{1,2} Pankuri Goraksha-Hicks,¹¹ Sharon J. Diskin,^{1,2,7,14,15} David I. Bellovin,¹⁶ M. Celeste Simon,^{1,2} Jeffrey C. Rathmell,^{11,12,13} Mitchell A. Lazar,^{8,9} John M. Maris,^{1,2,7,14,15} Dean W. Felsher,¹⁶ John B. Hogenesch,^{4,5} Aalim M. Weljie,^{3,4} and Chi V. Dang^{1,2,6,*}

¹Abramson Family Cancer Research Institute

²Abramson Cancer Center

³Department of Systems Pharmacology and Translational Therapeutics

⁴Department of Pharmacology

⁵Institute for Translational Medicine and Therapeutics

⁶Division of Hematology-Oncology, Department of Medicine

⁷Department of Pediatrics

⁸Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine

⁹The Institute for Diabetes, Obesity, and Metabolism

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

¹⁰Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

¹¹Department of Pharmacology and Cancer Biology

¹²Sarah W. Stedman Nutrition and Metabolism Center

¹³Department of Immunology

Duke University, Durham, NC 27710, USA

¹⁴Division of Oncology

¹⁵Center for Childhood Cancer Research

Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

¹⁶Division of Medical Oncology, Departments of Medicine and Pathology, Stanford School of Medicine, Stanford, CA 94304, USA

¹⁷Co-first author

*Correspondence: dangvchi@exchange.upenn.edu

<http://dx.doi.org/10.1016/j.cmet.2015.09.003>

SUMMARY

The *MYC* oncogene encodes MYC, a transcription factor that binds the genome through sites termed E-boxes (5'-CACGTG-3'), which are identical to the binding sites of the heterodimeric CLOCK-BMAL1 master circadian transcription factor. Hence, we hypothesized that ectopic MYC expression perturbs the clock by deregulating E-box-driven components of the circadian network in cancer cells. We report here that deregulated expression of MYC or N-MYC disrupts the molecular clock in vitro by directly inducing REV-ERB α to dampen expression and oscillation of BMAL1, and this could be rescued by knockdown of REV-ERB. REV-ERB α expression predicts poor clinical outcome for N-MYC-driven human neuroblastomas that have diminished BMAL1 expression, and re-expression of ectopic BMAL1 in neuroblastoma cell lines suppresses their clonogenicity. Further, ectopic MYC profoundly alters oscillation of glucose metabolism and perturbs glutaminolysis. Our results demonstrate an unsuspected link between oncogenic transformation and circadian and metabolic dysrhythmia, which we surmise to be advantageous for cancer.

INTRODUCTION

The molecular clock regulates rhythmic gene expression and synchronizes cellular metabolism with food availability and the 24-hr sleep-wake cycle (Asher and Schibler, 2011; Bass and Takahashi, 2010; Sahar and Sassone-Corsi, 2012). Cancer cells are known for having a growth advantage from deregulated metabolism, such as through MYC-driven aerobic glycolysis or glutaminolysis that supports biosynthesis and cell growth, but it is unknown how or whether the MYC oncogenic transcription factor could disrupt and uncouple metabolism from the influence of the molecular clock (Cantor and Sabatini, 2012).

Oncogenic expression of the MYC family of transcription factors lies at the center of many human cancers (Dang, 2012; Eilers and Eisenman, 2008). The MYC (c-MYC) gene is frequently amplified in human cancers (Ciriello et al., 2013), and the highly related MYCN (N-MYC) is amplified in poor-prognosis neuroblastoma (Maris, 2010). MYC heterodimerizes with its partner MAX to bind E-box sequences or non-canonical sites in target gene promoters or enhancers and regulate transcription (Wolf et al., 2015). Aberrant expression of MYC results in upregulation of many target genes, particularly those involved in glycolysis, oxidative metabolism, glutamine metabolism, mitochondrial and ribosomal biogenesis, cell growth, and cell cycle regulation (Eilers and Eisenman, 2008). Intriguingly, while MYC has not been previously implicated in control or regulation of circadian rhythm in cancer cells, E-box elements bound by MYC drive expression of metabolic genes, such as nicotinamide

phosphoribosyltransferase (*NAMPT*) (Menssen et al., 2012), that are also bound by the central molecular clock heterodimeric transcription factor CLOCK-BMAL1, which controls rhythmic circadian gene expression (Dang, 2012; Hogenesch et al., 1998; Ramsey et al., 2009). The molecular clock is driven by a key feedback loop, in which CLOCK-BMAL1 induces *PER* and *CRY* proteins, which in turn form inhibitory complexes with CLOCK-BMAL1 (Sato et al., 2006). CLOCK-BMAL1 also induces *REV-ERB α* and *REV-ERB β* (Bugge et al., 2012; Cho et al., 2012), which transcriptionally repress BMAL1 at retinoic acid receptor-related orphan receptor elements (ROREs), thereby constituting a second important interlocking feedback loop (Preitner et al., 2002).

Circadian rhythms are ~24-hr cycles that control metabolic gene expression and cell division as well as other physiological processes, such as blood pressure and body temperature, coupling food availability and sleep with cellular metabolism (Bass and Takahashi, 2010). In mammals, the central clock is located within the suprachiasmatic nucleus (SCN) of the brain that senses light and synchronizes peripheral clocks through humoral, neuronal, and behavioral cues (Bass and Takahashi, 2010). The peripheral clocks, which are present in nearly every cell in the body (Bass and Takahashi, 2010), operate independently from the central clock and can be entrained by feeding in addition to temperature and synchronization cues from the central clock.

Mutations of circadian genes occur in many cancers, but their functional consequences are not well understood (Savvidis and Koutsilieris, 2012). Two key circadian genes, *PER1* and *PER2*, have been identified as putative tumor suppressors in salivary gland, gastro-intestinal system, breast tissue, and the immune compartment (Savvidis and Koutsilieris, 2012; Zhao et al., 2014). Loss of *PER2* function predisposed genetically engineered mice to spontaneous lymphomagenesis, but mouse strain specificity was not documented (Fu et al., 2002). Hematologic malignancies such as diffuse large B cell lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia show strong downregulation of the central circadian regulator BMAL1 (Taniguchi et al., 2009). Indeed, recent studies identify BMAL1 as a putative tumor suppressor (Savvidis and Koutsilieris, 2012; Yeh et al., 2014). Ovarian cancers have altered circadian gene expression and oscillation compared to normal tissue, but the functional significance and mechanism for these alterations were not established (Tokunaga et al., 2008). Still other studies found circadian gene expression alterations in cancers such as pancreatic, prostate, and glioma (Savvidis and Koutsilieris, 2012). Importantly, altered circadian rhythm may affect cancer treatment outcomes, as studies in mice and humans have identified circadian-dependent toxicity in more than 40 anti-cancer agents, including antimetabolites, mitosis inhibitors, alkylating agents, and cytokines (Lévi et al., 2010). Thus, altered circadian gene expression occurs broadly in cancer; however, it is not known whether *MYC* could contribute to disruption of circadian gene expression.

Given that the target core consensus sequence of CLOCK-BMAL1 appears identical to those recognized by *MYC*, we have previously hypothesized that oncogenic *MYC* could disrupt the molecular clock in vitro through dysregulating E-box-driven components of the clock machinery and thereby perturb circa-

dian influence of central bioenergetic metabolism (Dang, 2012). Here, we report that *MYC* directly activates expression of multiple repressors of the clock and disrupts the circadian oscillation of the BMAL1::luciferase reporter and BMAL1 (*ARNTL*) mRNA. Through loss-of-function studies, we found that *REV-ERB* induction by *MYC* functionally contributes to the repression and dampening of BMAL1 oscillation. Further, N-*MYC* also induces *REV-ERB α* (*NR1D1*), whose elevated expression suppresses BMAL1 and portends poor clinical outcome for neuroblastoma patients. We also found that ectopic expression of BMAL1 reduces the clonogenicity of neuroblastoma cell lines, supporting the putative tumor suppressive function of BMAL1 (Yeh et al., 2014). Importantly, we found that *MYC* not only disrupts the circadian clock, but it also profoundly perturbs circadian glucose metabolism and glutaminolysis, favoring *MYC*-induced biosynthesis for cell growth. Our findings indicate that *MYC* and N-*MYC*, which are frequently deregulated in human cancers, can disrupt the cellular molecular clock and significantly affect cellular metabolism.

RESULTS

MYC Disrupts Circadian Oscillation of BMAL1 Levels in Cultured Cells

We sought to determine whether ectopic *MYC* expression could disrupt the cellular clock machinery. We used the human osteosarcoma cell line U2OS, which is a commonly used line to study circadian rhythm and has been engineered to stably express luciferase under the control of the BMAL1 promoter such that circadian oscillation of luciferase can be observed with the LumiCycle luminometer in real time after synchronizing the cells with dexamethasone (Baggs et al., 2009; Balsalobre et al., 2000). As U2OS cells have relatively low endogenous *MYC* (Walz et al., 2014), we stably expressed inducible wild-type *MYC-ERTM* (estrogen receptor tamoxifen mutant) or a mutant *MYC-ERTM* Δ 106-143, which lacks the transactivation *MYC* Box II domain (Littlewood et al., 1995) (Figure 1A inset). When stimulated with 4-hydroxytamoxifen (4OHT, *MYC-ON*), *MYC-ER* translocated into nucleus and upregulated the *MYC* targets ornithine decarboxylase 1 (*ODC1*) and *NAMPT*, demonstrating the increased activity of *MYC* (Figure 1B) (Menssen et al., 2012; Walz et al., 2014). In contrast, cells expressing mutant *MYC-ER* Δ 106-143 showed only slight upregulation of *ODC1* and no upregulation of *NAMPT* in response to 4OHT stimulation (Figure 1C). While vehicle-treated (EtOH-treated, *MYC-OFF*) dexamethasone-synchronized U2OS *MYC-ER* cells showed 24-hr oscillation of luciferase, activation of *MYC-ER* with 4OHT profoundly ablated this oscillation (Figures 1A and S1A). By contrast, this oscillation was not diminished in *MYC-ER* Δ 106-143-expressing cells treated with 4OHT (Figures 1A and S1A) or in cells that were uninfected or transduced with control empty vector (Figures 1D and S1B). Collectively, these observations documented that wild-type *MYC* activity dampens the oscillating circadian activity of the BMAL1 promoter.

Next, we collected RNA every 4 hr and assessed endogenous circadian gene expression by qPCR in synchronized U2OS cells. Endogenous BMAL1 (*ARNTL*) mRNA level was strongly decreased and oscillation significantly blunted by *MYC* activation (Figure 1E). The endogenous core circadian factor *PER2*




Figure 1. MYC Disrupts Circadian Rhythm

(A) U2OS BMAL1::Luc cells stably expressing either human wild-type MYC-ERTM or human MYC-ERTM Δ 106-143 (as visualized by immunoblot, inset) were treated with 4-hydroxytamoxifen (4OHT, MYC-ON) to activate MYC-ERTM or ethanol (EtOH, MYC-OFF) control and synchronized with dexamethasone. BMAL1 promoter activity luminescence was continuously measured (every 10 min) in a LumiCycle luminometer. Data are representative of more than three experiments.

(B and C) Expression of ornithine decarboxylase (ODC1) or NAMPT in U2OS MYC-ERTM (B) or MYC-ERTM Δ 106-143 cells (C) as determined by RT-PCR, normalized to beta-2-microglobulin (β 2M). Data are shown as means \pm SD (n = 4). mRNA (FC) = Fold Change, ns = not significant.

(D) U2OS BMAL1::Luc cells expressing pBabe-Zeo empty vector (ev) or mock infected were cultured with 4OHT or ethanol, synchronized with dexamethasone, and monitored in LumiCycle luminometer. Data are representative of three or more experiments.

(E and F) Endogenous BMAL1 (E) or *PER2* mRNA expression (F) in synchronized U2OS MYC-ER cells was determined by RT-PCR, normalized to β 2M. Data are representative of two or more experiments.

(G) Immunoblot of tetracycline regulated MYC in mHCC 3-4 cells. Tubulin serves as loading control. (H) Expression of ODC1 and NAMPT in mHCC 3-4 cells as determined by RT-PCR. Data are shown as means \pm SD (n = 5).

(I) mHCC 3-4 BMAL1::Luc cell clone (c12) treated with tetracycline (tet, MYC-OFF) or control (-tet, MYC-ON) and synchronized with dexamethasone was monitored as in (A). RLU = relative light units. For (B), (C), and (H), *p < 0.05 by Student's t test of MYC-ON samples relative MYC-OFF samples.

mRNA level was increased, but oscillation was also altered by MYC (Figure 1F). The fact that *PER2* continued to oscillate with a disrupted phase is consistent with previously published results showing that static BMAL1 mRNA expression alters but does not eliminate *PER* oscillation (McDearmon et al., 2006). These data indicated that MYC affects not only the BMAL1 promoter-reporter, but also endogenous cycling of circadian genes.

To determine whether MYC-mediated disruption of circadian oscillation of BMAL1 promoter function could be restored in cancer, we used the mouse hepatocellular carcinoma cell line mHCC 3-4 derived from a liver tumor with a conditional c-MYC Tet-Off expression system (Shachaf et al., 2004; Xiang et al., 2015) (Figure 1G). Ectopic MYC predictably increased levels of *Odc1* and *Nampt* mRNAs (Figure 1H). As previously done in U2OS cells (Baggs et al., 2009), we produced MYC-transformed mHCC 3-4 cells that stably express BMAL1::Luc. By LumiCycle

luminometer analysis, circadian oscillation was restored with diminished ectopic MYC expression in this mouse liver cancer-derived cell line in multiple clones (Figures 1I, S1C, and S1D). Reduction of ectopic MYC expression also appeared to restore the expression of BMAL1 (*Arntl*) mRNA at later time points (Figure S1E) and reduced *Per2* mRNA levels (Figure S1F). These observations collectively indicated that MYC overexpression alters circadian oscillation in different cell types and that diminished MYC expression in a MYC-driven tumor-derived liver cancer cell line could partially restore BMAL1 promoter activity oscillation.

MYC Upregulates Circadian Repressor Genes and Downregulates BMAL1 Expression

To delineate the mechanism by which MYC disrupts BMAL1 oscillation, we hypothesized that MYC transactivates E-box-driven BMAL1 repressors, such as *PER* and *CRY*, REV-ERB α (*NR1D1*), or REV-ERB β (*NR1D2*) (Bass, 2012; Bass and Takahashi, 2010). We observed that MYC significantly upregulated levels of *PER2*, *CRY1*, REV-ERB α , and REV-ERB β mRNAs in both U2OS MYC-ER (Figure 2A) and mHCC 3-4 (Figure 2B) cells.




Figure 2. MYC Upregulates Circadian Repressor Genes

(A) Expression of clock factor genes (indicated above each graph) in (A) U2OS MYC-ER cells treated with either 4OHT (MYC-ON) or EtOH (MYC-OFF) control for 24 hr.

(B) mHCC 3-4 cells treated with (+Tet, MYC-OFF) or without (-Tet, MYC-ON) tetracycline for 24 hr, or (C) U2OS MYC-ERTM Δ 106-143 cells treated with either 4OHT (MYC-ON) or EtOH (MYC-OFF) control for 24 hr. mRNA expression determined by RT-PCR was normalized to β 2M expression. mRNA (FC) = Fold Change. Means and SDs from at least three experiments are shown. * $p < 0.05$ by Student's t test of 4OHT (MYC-ON) samples relative to EtOH (MYC-OFF) samples or -Tet (MYC-ON) samples relative to +Tet (MYC-OFF) samples, ns = not significant.

REV-ERB α and β Are Necessary for Disruption of Circadian Rhythm by MYC

To delineate which BMAL1 repressors were responsible for disruption of circadian rhythm, we used siRNAs against the repressors to determine whether diminished expression could rescue MYC-mediated disruption of BMAL1-promoter circadian rhythm. *PER* and *CRY* negatively regulate circadian rhythm by repressing CLOCK-BMAL1 activity (Bass, 2012; Bass and Takahashi, 2010). We used siRNAs targeting *CRY1* and *PER2*, which were consistently induced by MYC in multiple cell lines (Figure 2), in U2OS cells expressing MYC-ER to determine if they were responsible for the downregulation of BMAL1 and disruption of circadian oscillation by MYC. While we observed a significant reduction in the expression of each gene after siRNA

Some variation was observed between cell lines, as *Per1* was upregulated by MYC in mHCC 3-4 but not in U2OS MYC-ER. In contrast to wild-type MYC, the inactive MYC-ER Δ 106-143 mutant did not show significant upregulation of any circadian genes upon treatment with 4OHT, and slight downregulation of steady-state BMAL1 expression in U2OS cells (Figure 2C). To determine whether *PER*, *CRY*, REV-ERB α , and REV-ERB β behave as direct MYC target genes, we analyzed publicly available MYC chromatin immunoprecipitation (ChIP) data from multiple cancer cell lines and U2OS cells with inducible MYC, and we also performed promoter studies with U2OS and mHCC (see Supplemental Experimental Procedures and Figures S2 and S3A–S3C). We found that each of these genes, with the exception of BMAL1 (*ARNTL*), could be induced and bound by MYC and hence behave as direct MYC targets in multiple cell lines. These observations suggested that MYC could induce the expression of negative regulators of BMAL1, which can in turn disrupt the molecular clock in vitro.

treatment (Figure 3A), neither *PER2* nor *CRY1* knockdown significantly rescued either BMAL1 mRNA expression suppressed by MYC (Figure 3B) or the blunted BMAL1::Luc oscillation in MYC-ER-activated U2OS cells (Figure 3C). These data suggest that while *PER2* and *CRY1* behave as MYC targets, they may not be functionally responsible for disruption of BMAL1::Luc oscillation by MYC in U2OS cells. However, MYC's induction of *PER2* and *CRY1* may still alter the molecular clock, because of their effects on BMAL1 protein activity rather than BMAL1 mRNA. Further, their reduction by siRNA to non-basal level could confound the interpretation of their roles in the suppression of BMAL1::Luc by MYC.

REV-ERB α is a transcriptional repressor that blunts BMAL1 expression and oscillation in U2OS cells (Preitner et al., 2002; Relógio et al., 2011). Further, overexpression of REV-ERB α in transgenic mouse liver suppressed BMAL1 levels and oscillation in vivo (Kornmann et al., 2007). REV-ERB α closely cooperates with REV-ERB β to regulate gene expression and occupy




Figure 3. REV-ERB α and β Are Necessary for MYC Disruption of BMAL1 Promoter Oscillation

(A) mRNA levels (normalized to expression of $\beta 2M$) for *PER2* or *CRY1* determined by RT-PCR in U2OS MYC-ER cells transfected with either non-targeting siRNA (Con), siRNA against *PER2*, or *CRY1* for 48 hr with 4OHT (MYC-ON) being added to cells 24 hr after transfection. Means and SDs from at least three experiments are shown. * $p < 0.05$ for Con versus siPER2 or siCRY1. mRNA (FC) = Fold Change.

(B) BMAL1 mRNA expression (normalized to expression of $\beta 2M$) in U2OS MYC-ER transfected as described in (A) with siRNAs indicated at the bottom. * $p < 0.05$ by Student's t test for MYC-ON versus MYC-OFF. ns = not significant.

(C) U2OS MYC-ER cells were transfected with siRNAs as indicated in the figure, synchronized with dexamethasone and monitored using a LumiCycle luminometer. Data are representative of two or more experiments.

(D) mRNA levels (normalized to expression of $\beta 2M$) for REV-ERB α or REV-ERB β determined by RT-PCR in U2OS MYC-ER cells transfected with either non-targeting siRNA (Con), siRNA against REV-ERB α , REV-ERB β , or both REV-ERBs ($\alpha + \beta$) for 48 hr with 4OHT (MYC-ON) being added to cells 24 hr after transfection. Means and SDs from at least three experiments are shown. * $p < 0.05$ for siREV versus control.

(E) BMAL1 mRNA levels (normalized to expression of $\beta 2M$) in U2OS MYC-ER transfected with the indicated siRNAs (bottom) as described in (D) and cultured with 4OHT (MYC-ON) or EtOH (MYC-OFF) after 24 hr. Means and SDs from at least three experiments are shown. * $p < 0.05$ by Student's t test for siREV or Con MYC-ON versus Con MYC-OFF. §, $p < 0.05$ siREV versus Con MYC-ON.

(F) U2OS MYC-ER cells transfected with the indicated siRNAs for 48 hr, cultured with 4OHT (MYC-ON) or EtOH (MYC-OFF), synchronized with dexamethasone, and monitored as in (C). Data are representative of two or more experiments. RLU = relative light units.

of either REV-ERB α or REV-ERB β increased BMAL1 expression in MYC-activated cells, knockdown of both genes together led to a complete rescue of BMAL1 expression in the presence of MYC (Figure 3E). Note that REV-ERB knockdown in MYC-OFF cells also increased basal BMAL1 mRNA levels as expected (Figure 3E). Knockdown of REV-ERB α in mHCC 3-4 cells also led to a significant rescue in BMAL1 mRNA expression (Figure S3D). Importantly, knocking down both REV-ERB mRNAs substantially

rescued the MYC-ER-mediated dampened expression and oscillation of BMAL1::Luc in U2OS cells, while individual REV-ERB gene knockdown could partially rescue the dampening effects of MYC (Figure 3F). These data suggested that MYC's disruption of circadian rhythm is largely carried out through MYC-mediated upregulation of REV-ERB transcription. In fact, we also observed that high MYC expression in a panel of

rescued the MYC-ER-mediated dampened expression and oscillation of BMAL1::Luc in U2OS cells, while individual REV-ERB gene knockdown could partially rescue the dampening effects of MYC (Figure 3F). These data suggested that MYC's disruption of circadian rhythm is largely carried out through MYC-mediated upregulation of REV-ERB transcription. In fact, we also observed that high MYC expression in a panel of




Figure 4. N-MYC Directly Upregulates REV-ERB α and Disrupts Circadian Rhythm

(A) REV-ERB α and BMAL1 mRNA expression (normalized to expression of $\beta 2M$) determined by RT-PCR in Shep N-MYC-ER expressing neuroblastoma cells with MYC-ON or MYC-OFF. mRNA (FC) = Fold Change. Means and SDs from at least three experiments are shown. * $p < 0.05$ by Student's t test for MYC-ON versus MYC-OFF.

(B) Chromatin immunoprecipitation (ChIP) analysis with anti-N-MYC antibody in MYC-ON versus MYC-OFF in Shep N-MYC-ER cells. ChIP signals (% input) are shown for the Rev-erb α promoter E-box region (REV α , 81 bp region), 2 kb upstream of REV-ERB α transcription start site (REV α -2k), and the promoter of the canonical MYC target nucleophosmin 1 (NPM1). Means and SDs from technical triplicates are shown. * $p < 0.05$ by Student's t test for MYC-ON versus MYC-OFF. Data are representative of three or more experiments.

(C) Activity of the REV-ERB α promoter: luciferase construct (-1156 to +31 region) in Shep N-MYC-ER-expressing cells expressing under MYC-ON versus MYC-OFF conditions. RLU: relative light unit. Means and SDs from triplicate samples are shown, and * $p < 0.05$ by Student's t test for MYC-ON versus MYC-OFF. Data are representative of three or more experiments.

(D) Time series (every 4 hr) expression of BMAL1 (left panel) or PER2 (right panel) mRNA (relative to $\beta 2M$) determined by RT-PCR in synchronized Shep N-MYC-ER-expressing cells with MYC-ON or MYC-OFF. Data are representative of two or more experiments.

(E) Kaplan-Meier survival analysis of patients with neuroblastoma expressing different levels of MYCN or (REV-ERB α) NR1D1 analysis grouped by tertiles based on individual gene expression. Log rank p values are shown.

(F) Ectopic expression of BMAL1 (ARNTL, specific band indicated by <) in the high MYCN neuroblastoma cell lines NLF and Kelly was determined by immunoblotting, with Tubulin serving as a loading control.

(G) Colony suppression assay of cells treated with 1 mg/ml G418 showed that ectopic expres-

sion of ARNTL suppressed colony formation capacities of NLF and Kelly cells as compared with vector control (ev).

(H) Quantitation of colony suppression by ARNTL determined by area of colonies on culture plates measured by ImageJ. $n = 3$, error bars represent SD. * $p < 0.05$ by Student's t test.

human-derived T-ALL (T cell acute lymphoblastic leukemia) lines correlates with increased REV-ERB α expression (Figures S3E and S3F).

N-MYC Disrupts Circadian Gene Expression and Oscillation

It has been shown previously that c-MYC and N-MYC, encoded by the MYCN gene, have overlapping functions, targets, and binding motifs (Malynn et al., 2000). Given the functional similarities between MYC and N-MYC, we sought to determine whether N-MYC could also induce REV-ERB α expression like MYC. To study N-MYC, we used the human neuroblastoma cell lines Shep N-MYC-ER and SKNAS N-MYC-ER (Ushmorov et al., 2008; Valentijn et al., 2005). Both Shep and SKNAS lack amplified N-MYC, but when ectopic N-MYC-ER was activated with

4OHT (MYC-ON), the canonical Myc targets ODC1 and NAMPT were induced (Figures S4A and S4B). N-MYC activation also resulted in strong upregulation of REV-ERB α and downregulation of BMAL1 (Figures 4A and S4B). PER1, PER2, and CRY1 were similarly upregulated in the presence of 4OHT, suggesting that N-MYC perturbs circadian gene regulation like MYC (Figures S4A and S4B). These data suggest that inducible N-MYC similarly disrupts circadian gene expression in two different neuroblastoma cell lines.

Corroborating the findings with the N-MYC-ER models, REV-ERB α expression also positively tracks with expression of N-MYC in three different neuroblastoma cell lines (Shep, NLF, and Kelly) with varying MYCN expression levels (Figure S4D). Like MYC in U2OS cells, N-MYC directly bound the promoter regions of REV-ERB α and NPM1 in Shep N-MYC-ER, but not with

a region of DNA 2,000 bases upstream from the REV-ERB α promoter start site (Figure 4B). Shep N-MYC-ER cells expressing a REV-ERB α ::luciferase reporter also showed increased luciferase activity in the presence of 4OHT (Figure 4C), indicating that REV-ERB α is a direct target of N-MYC. Consistent with MYC upregulating REV-ERB α , Shep and SKNAS N-MYC-ER cells with active N-MYC-ER (MYC-ON) showed greatly diminished expression and disrupted oscillation of BMAL1 (Figures 4D and S4C), as well as increased amplitude and altered oscillation of *PER2* (Figures 4D and S4C), consistent with results from U2OS and mHCC 3-4 cells. Importantly, this same trend was found in the three neuroblastoma cell lines (Figure S4D); we observed some circadian BMAL1 oscillation in the N-MYC single copy Shep cells, but not in the N-MYC amplified NLF or Kelly lines (Figure S4E).

Increased REV-ERB α and Decreased BMAL1 Expression Correlate with High Risk Neuroblastoma, and BMAL1 Functions as a Tumor Suppressor in MYCN Amplified Neuroblastoma Cells

We analyzed gene expression from a collection of human primary neuroblastoma tumor samples to establish the potential clinical relevance of N-MYC regulation of REV-ERB α in human neuroblastoma (Wang et al., 2006). Consistent with previous findings, patients with the highest MYCN-expressing neuroblastomas had the worst survival outcomes (Figure 4E). Intriguingly, elevated REV-ERB α alone also highly correlated with poor prognosis (Figure 4E), suggesting that REV-ERB α may play a role in the aggressiveness of neuroblastoma. REV-ERB α (*NR1D1*) expression was elevated in high-risk tumors, particularly those with MYCN amplification, compared to tumors classified as low or intermediate risk (Figure S5A) (Pugh et al., 2013). Conversely, BMAL1 (*ARNTL*) expression was lowest in the high-risk MYCN-amplified group (Figure S5B). Further, low BMAL1 or high REV-ERB α expression also correlated with poor prognosis in two different patient cohorts (Figures S5C–S5E) (Kocak et al., 2013). Together, these data suggested that overexpressed N-MYC, as observed in cell lines and in primary patient samples, specifically upregulates REV-ERB α , which decreases BMAL1 expression and disrupts the molecular clock in neuroblastoma.

The decreased BMAL1 expression in high-risk neuroblastoma could be related to its putative tumor suppressor function (Yeh et al., 2014). To determine its tumor suppressive role, we overexpressed BMAL1 in NLF and Kelly neuroblastoma cell lines that have high N-MYC expression (Figure S4D) and assessed BMAL1's effect on colony formation. BMAL1 was expressed by transient transfection of pCMV6-*ARNTL* (BMAL1), and the pCMV6 empty vector (Ev) served as control (Figures 4F and 4G). Cells were then selected with G418 and stained with crystal violet. As shown in Figure 4H, ectopic BMAL1 expression significantly suppressed colony formation in both NLF and Kelly cells, illustrating a tumor suppressive function of BMAL1.

MYC Disrupts Circadian Oscillation of Glycolysis and pAMPK and Alters Glutamine Metabolism

To determine whether MYC-mediated disruption of the circadian transcription factor network altered metabolism, we performed targeted metabolomics using NMR focusing on glucose, lactate, glutamine, glutamate, and pyruvate levels in culture media and

U2OS MYC-ER cells. In a time-series experiment at 2 hr intervals, media and cells from MYC-OFF (EtOH) or MYC-ON (4OHT) conditions were harvested for measurements of metabolites over a period of 48 hr, 24 hr after dexamethasone synchronization, without changing the media. NMR peak intensities were quantified at each time point and were subjected to detrending and JTK (Jonckheere-Terpstra-Kendall) cycle analysis to identify oscillation among the selected metabolites (see Figure S6 for example NMR spectra) (Hughes et al., 2010; Weljie et al., 2006). As shown in Figure 5A, glucose was consumed at a higher rate in MYC-ON cells than MYC-OFF cells, which displayed phases of glucose consumption with slowed rates of loss from the media between 14 and 24 hr. Intriguingly, intracellular glucose levels oscillated in a circadian manner (JTK cycle time = 24 hr; p value = 0.052; “adjusted” intracellular levels reflect concentrations in the extracts and not actual intracellular concentrations), peaking at about 12 and 36 hr. By contrast, while MYC-ON cells consumed glucose from the media at a higher rate, intracellular glucose levels were so low that circadian oscillation is not discernible, suggesting that glucose was consumed for biosynthesis as postulated (Murphy et al., 2013).

Consistent with MYC-driven biosynthesis, MYC-ON U2OS cells had remarkably low intracellular lactate levels relative to MYC-OFF cells, while extracellular lactate levels in the media accumulated to high levels for MYC-ON cells compared with MYC-OFF cells (Figure 5A). It is notable that the apparent oscillation of media lactate levels in MYC-OFF cells paralleled changes in cellular glucose levels; however, the oscillation in the media did not reach statistical significance by JTK analysis. The significant disappearance of pyruvate from the medium of MYC-ON cells as compared with MYC-OFF cells (Figure 5A) supports the notion of MYC-driven biosynthesis, particularly since intracellular pyruvate levels were below the detection limit of this NMR approach. These patterns reveal a previously unsuspected circadian oscillation of glucose metabolism and its conversion to lactate in synchronized U2OS cells, which were disrupted by induction of MYC, suggesting that MYC-mediated disruption of the circadian clock perturbs metabolic oscillation.

We also examined glutamine and glutamate and found that U2OS cells readily consumed glutamine, and the consumption was further heightened by the induction of MYC (Figure 5A). Intracellular glutamine levels were below detection limit in both MYC-ON and MYC-OFF cells (not shown). Notably, media glutamate levels were generally higher for MYC-ON cells compared to MYC-OFF cells. Intracellular glutamate decreased in MYC-ON cells while it accumulated in MYC-OFF cells, seemingly in a circadian fashion (which did not reach statistical significance by JTK analysis), suggesting glutamine and derived glutamate were consumed for biosynthesis in MYC-ON cells. These observations collectively illustrate that circadian fluctuation of key metabolites involved in glycolysis and glutaminolysis in U2OS cells was profoundly disrupted by MYC activation, which is known to drive biosynthesis for cell growth (Murphy et al., 2013).

To gain further insight into the bioenergetics of U2OS cells with different MYC activities, we analyzed phosphorylated AMPK (pAMPK T172) as a surrogate measure of cellular energy status. As shown in Figure 5B, pAMPK levels were higher, particularly at later time points, and oscillating in MYC-OFF cells as compared




Figure 5. MYC Suppresses Circadian Oscillation of Glucose Metabolism and Alters Glutamine Metabolism in U2OS Cells

(A) Cellular (Cells) or media metabolite (top labels) levels determined by NMR spectroscopy are shown for a time-series experiment with 2-hr intervals from U2OS with MYC-OFF (EtOH) or MYC-ON (4OHT), 24 hr after initial dexamethasone synchronization. Concentrations for metabolites represent the *adjusted* concentration for cells, based on extraction volume, or the *actual* concentration of media metabolites. For each metabolite profile, the time-series data were plotted using the JTK v2 algorithm after linear detrending, and rhythmicity was assessed via a non-parametric cosine function fit. The colored bands represent 95% confidence intervals from the locally weighted scatterplot smoothing function that generated the curves. *p* values indicate the significance of the cosine wave fit to experimental data. Note that MYC-ON media 24-hr sample and MYC-ON cells 48-hr sample were excluded due to inconsistencies in sample measurements.

(B) Synchronized U2OS MYC-ER cells were harvested after treatment and lysates were processed for immunoblots of hexokinase 1 (HK1), hexokinase 2 (HK2), phospho-AMP kinase (pAMPK Thr172), AMP-kinase (AMPK), BMAL1, and PER2 (indicated by <). Tubulin serves as a loading control. Data are representative of two individual experiments.

with MYC-ON cells. Oscillation of pAMPK levels was in-phase with intracellular glucose levels and appears to correlate with high intracellular lactate levels (glycolysis). pAMPK levels were at their lowest level when intracellular glucose levels were lowest (Figure 5B) in MYC-OFF cells. Intriguingly, the levels and oscillation of pAMPK were suppressed in MYC-ON cells, suggesting that the bioenergetics status of MYC-driven U2OS cells was sustained by increased glutaminolysis and consumption of glucose. We also determined levels of hexokinases, HK1 and HK2, and found that both enzyme levels, particularly HK1, appear to oscillate (minimally) in phase with glucose consumption in MYC-OFF cells (Figure 5B). However, in MYC-ON cells, HK2, a known MYC target (Kim et al., 2007), was induced and ceased to oscillate. Note that these changes correspond to MYC-induced decreased BMAL1 and increased PER2 protein levels (Figure 5B). These observations demonstrate that, in addition to metabolic oscillation, the bioenergetic status of MYC-OFF U2OS cells also oscillated in a manner that is suppressed by

ectopic MYC activity, which drives glycolysis and glutaminolysis for biosynthesis.

DISCUSSION

MYC and circadian rhythm are frequently altered in cancer (Sahar and Sassone-Corsi, 2009), but whether this altered circadian rhythm can be mechanistically linked to deregulated MYC transcriptional function in cancer has not been determined. Our work here documents the previously unsuspected role of oncogenic MYC in the disruption of the molecular clock and metabolic oscillation in vitro, providing a foundation for future in vivo studies. We found that oncogenic MYC disrupts circadian oscillation through upregulation of REV-ERB α and REV-ERB β , which in turn dampen BMAL1 expression and oscillation (Figure 6); however, we have not excluded the possible roles of MYC-induced CRY and PER in MYC-mediated clock disruption. Specifically, it is notable that MYC increased PER2 mRNA and protein levels while perturbing the circadian oscillation of PER2 expression (Figures 1F and 5B). We demonstrate that MYC directly bound to the promoter of REV-ERB α and upregulated its transcription, leading to lower levels of BMAL1 expression and loss of rhythmicity. These data are consistent with previous studies showing that ectopic REV-ERB α expression can dampen the oscillation of BMAL1, both in vitro and in vivo (Kornmann et al., 2007; Relógio et al., 2011). Our finding that MYC could occupy circadian E-boxes as previously proposed (Kondratov et al., 2006) is




Figure 6. Model of Circadian Rhythm Disruption by MYC

(A and B) Summary diagram of normal molecular clock (A) and molecular clock disrupted by MYC (B).

consistent with a study showing that the E-box binding helix-loop-helix leucine zipper transcription factor USF1 can also compete with CLOCK-BMAL1 to bind to circadian regulatory elements (Shimomura et al., 2013). However, we have not distinguished between E-box co-occupancy or competition between MYC and CLOCK-BMAL1.

During the course of our studies, a recent report documented a role for MYC in disrupting the emergence of the circadian clock during differentiation of embryonic stem cells (Umemura et al., 2014). However, in these normal cells, MYC disruption of the circadian clock was dominated by a block in PER nuclear import rather than a direct effect on circadian E-boxes as we demonstrated in cancer cell lines. Our observations underscore the complexity of MYC-mediated transcription, which does not simply amplify expression of genes that are already expressed. Rather, MYC-mediated gene expression culminates from the intricate interplay between MYC and other transcription factors such as MIZ-1, which can result in time-dependent gene expression changes particularly when the molecular clock transcription factors are involved (Wolf et al., 2015).

While REV-ERB α was universally upregulated by MYC and N-MYC in all cell lines and databases we queried, REV-ERB β up-regulation was less consistent across these cell lines, despite also being predicted as a MYC target. Nonetheless, knockdown of both REV-ERB β and REV-ERB α was required to substantially rescue BMAL1::luciferase amplitude and oscillation, which were inhibited by MYC. These observations are consistent with previous findings that REV-ERB α and REV-ERB β cooperate closely to

regulate transcription (Bugge et al., 2012; Cho et al., 2012), and, as such, both would have to be considered together when studying circadian gene oscillation.

Our observation that REV-ERB α expression induced by N-MYC correlates with poor prognosis for neuroblastoma contributes to the notion that REV-ERB α expression might be important in tumorigenesis. Notably, the REV-ERB α gene is co-amplified with *ERBB2* in some breast cancers and may play an important role in the growth of the breast cancer cells (Kourtidis et al., 2010). REV-ERB α has not been previously recognized as an oncogene, but its suppression of BMAL1 could contribute to its tumorigenic potential. In particular, BMAL1 has been implicated as a tumor suppressor (Yeh et al., 2014), and our studies corroborate this notion and illustrate that low BMAL1 expression correlates with high-risk neuroblastoma and that ectopic expression of BMAL1 suppressed colony formation by two different high N-MYC neuroblastoma cell lines.

Given that circadian rhythm controls metabolic function, circadian oscillation therefore constrains metabolism at certain times of the day (Bass, 2012). Hence, perturbation of circadian gene expression, as is broadly found in cancer, could release the circadian restraints on cancer metabolism. MYC can elevate metabolic gene expression in transformed cells compared to normal cells (Dang, 2012), whose expression of metabolic genes is constrained by the molecular clock. We speculate that MYC induction of REV-ERB α , which in turn suppresses BMAL1, could lead to elevated, unconstrained expression of metabolic genes through clock disruption to provide an advantage to cancer cells. In this regard, we found for the first time that intracellular glucose metabolism in synchronized U2OS cells oscillated in a circadian fashion that was profoundly disrupted by MYC activation, which induced high levels of HK2 and increase glucose flux and lactate production. Our observations are consistent with a recent study showing circadian oscillation of NADH/NAD $^{+}$ ratio in epidermal stem cells (Stringari et al., 2015). Significant changes in pAMPK, lactate, pyruvate, glutamine, and glutamate in our studies are consistent with a role of activated MYC in driving biosynthesis, which correlates MYC's ability to disrupt the circadian molecular clock. However, our current study does not define the interplay between MYC's transcriptional disruption of the circadian clock machinery and its direct regulation of metabolic genes. Further studies will be required to parse the roles of MYC in genetic and metabolic regulation of circadian rhythm.

Because *MYC* and *MYCN* are amplified or their expressions are altered in at least 50% of cancers (Dang, 2012), our work suggests that a large group of cancers may have disrupted circadian molecular clocks and metabolism. While the potential tumorigenic advantage of an oncogene-disrupted circadian rhythm needs to be further established in the future through in vivo studies, we speculate that the differences between normal cellular circadian gene expression and the arrhythmic expression of circadian genes in cancer cells could potentially be exploited to optimize cancer therapy.

EXPERIMENTAL PROCEDURES

Detailed Experimental Procedures, including standard molecular techniques such as PCR, immunoblotting, cell culture, transfection, and genomics studies are described in the [Supplemental Information](#).

Real-Time Luminescence Monitoring

Lumicycle analysis of U2OS BMAL1::Luc cells was described previously (Baggs et al., 2009). Cell culture plates were cultured with beetle luciferin (Promega), sealed with high vacuum grease (Dow Corning), and measured for luminescence after dexamethasone synchronization every 10 min for at least 4 days on a Lumicycle luminometer, then presented as relative light units (RLU) per second (Actimetrics). The experiments were performed with technical triplicates and multiple biological replicates.

Time-Series mRNA Experiments

MYC was activated one day prior to collection. Experiment was performed as a “split time course.” Twenty-four hours prior to the start of the experiment, half the cells were synchronized in dexamethasone, and at the start, the other half of the cells were synchronized. At each time point, two plates were harvested representing 0 and 24 hr +dex, 4 and 28, etc., to arrive at a 52 hr time course.

Generation of Cell Lines and Clonogenic Assay

Cells were transfected and selected as described in the [Supplemental Information](#). For neuroblastoma clonogenic suppression, *ARNTL* or control expression vectors were transfected and cells were selected with G418 before staining with crystal violet. Plates were scanned and quantified with ImageJ, and representative images were uniformly contrasted.

siRNA

Human or mouse SMARTpool siRNAs were purchased from Dharmacon (GE Healthcare). Cells were transfected with siRNAs using Lipofectamine 2000 or RNAiMAX (Life Technologies). Non-targeting siRNAs with same molar amount were used as negative control. For all experiments, a total of 60 nM siRNA was used. For experiments in which REV-ERB α and REV-ERB β were used together in [Figure 3](#), 30 nM of each siRNA was used.

Primary Neuroblastoma Survival Data

For data in [Figure 4](#), previously published data (Wang et al., 2006) for 92 human tumors were assessed for overall survival based on *MYCN*, *NR1D1*, and *ARNTL* expression ([Figure S5C](#)). Survival analyses were performed using the methods of Kaplan and Meier. Patients were divided into separate groups based on tertiles of individual mRNA expression. For overall survival (OS), time was defined as the time from diagnosis until the time of death from disease or until the time of last contact if death did not occur. Patients who were alive were censored at the time last known alive. Log rank p values < 0.05 were considered significant. Databases used were GEO: GSE3960, GSE45547 (Wang et al., 2006; Kocak et al., 2013) and dbGap: phs000467 (Pugh et al., 2013).

Cell and Media Extraction for NMR Analysis

Snap-frozen U2OS cell pellets were thawed and extracted. The aqueous fraction of an organic:aqueous extraction was dried and immediately prepared for NMR analysis as described in the [Supplemental Information](#) using an Avance III HD 700 MHz NMR spectrometer from Bruker Biospin.

Quantitative Analysis of Metabolite Oscillations

Output concentrations from the NMR analysis were imported into the R statistical framework (<http://www.R-project.org>) and were noted to have significant temporal change in overall concentrations. Oscillations were assessed using the non-parametric JTK_CYCLE algorithm (Hughes et al., 2010), testing for period lengths between 22 and 26 hr corresponding to circadian events. The default cosine function was used to assess rhythmic patterns and significance.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and six figures and can be found with this article online at <http://dx.doi.org/10.1016/j.cmet.2015.09.003>.

AUTHOR CONTRIBUTIONS

Conceptualization, B.J.A., A.L.H., C.V.D.; methodology, B.J.A., A.L.H., A.V., D.I.B., M.C.S., M.A.L., D.W.F., J.B.H., A.M.W., C.V.D.; formal analysis,

B.J.A., A.L.H., S.J.D., A.M.W.; investigation, B.J.A., A.L.H., A.S., S.Y.K., Z.E.W., A.M.G., P.G.H., S.J.D., A.M.W.; resources, Z.E.S., A.V., B.L., S.J.D., D.I.B., M.C.S., J.C.R., J.M.M., D.W.F., J.B.H., A.M.W., C.V.D.; writing (original draft), B.J.A., A.L.H., C.V.D.; writing (review and editing), B.J.A., A.L.H., Z.E.S., Z.E.W., J.B.H., A.M.W., C.V.D.; visualization, B.J.A., A.L.H., Z.E.S., S.J.D., A.M.W., C.V.D.; supervision, C.V.D.; funding acquisition, B.J.A., C.V.D.

ACKNOWLEDGMENTS

We thank Michael Hogarty (University of Pennsylvania) for the Shep N-MYC-ER cells, Linda Valentijn (University of Amsterdam) for the SKNAS N-MYC-ER line, and Kathryn E. Wellen (University of Pennsylvania) for advice. We thank Brian Keith (University of Pennsylvania) for critical comments and suggestions on the manuscript. This work is partially supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) R01CA057341 (C.V.D.), The Leukemia and Lymphoma Society LLS 6106-14 (C.V.D.), and the Abramson Family Cancer Research Institute. B.J.A., Z.E.S., and Z.E.W. were supported by the NCI F32CA180370, F32CA174148, and F30CA200347, respectively. J.M.M. contribution of neuroblastoma data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project was supported by RC1MD004418. The authors declare no competing financial interests.

Received: July 8, 2015

Revised: August 25, 2015

Accepted: September 8, 2015

Published: September 17, 2015

REFERENCES

- Asher, G., and Schibler, U. (2011). Crosstalk between components of circadian and metabolic cycles in mammals. *Cell Metab.* 13, 125–137.
- Baggs, J.E., Price, T.S., DiTacchio, L., Panda, S., Fitzgerald, G.A., and Hogenesch, J.B. (2009). Network features of the mammalian circadian clock. *PLoS Biol.* 7, e52.
- Balsalobre, A., Brown, S.A., Marcacci, L., Tronche, F., Kellendonk, C., Reichardt, H.M., Schütz, G., and Schibler, U. (2000). Resetting of circadian time in peripheral tissues by glucocorticoid signaling. *Science* 289, 2344–2347.
- Bass, J. (2012). Circadian topology of metabolism. *Nature* 491, 348–356.
- Bass, J., and Takahashi, J.S. (2010). Circadian integration of metabolism and energetics. *Science* 330, 1349–1354.
- Bugge, A., Feng, D., Everett, L.J., Briggs, E.R., Mullican, S.E., Wang, F., Jager, J., and Lazar, M.A. (2012). Rev-erb α and Rev-erb β coordinately protect the circadian clock and normal metabolic function. *Genes Dev.* 26, 657–667.
- Cantor, J.R., and Sabatini, D.M. (2012). Cancer cell metabolism: one hallmark, many faces. *Cancer Discov.* 2, 881–898.
- Cho, H., Zhao, X., Hatori, M., Yu, R.T., Barish, G.D., Lam, M.T., Chong, L.W., DiTacchio, L., Atkins, A.R., Glass, C.K., et al. (2012). Regulation of circadian behaviour and metabolism by REV-ERB- α and REV-ERB- β . *Nature* 485, 123–127.
- Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N., and Sander, C. (2013). Emerging landscape of oncogenic signatures across human cancers. *Nat. Genet.* 45, 1127–1133.
- Dang, C.V. (2012). MYC on the path to cancer. *Cell* 149, 22–35.
- Eilers, M., and Eisenman, R.N. (2008). Myc's broad reach. *Genes Dev.* 22, 2755–2766.
- Fu, L., Pelicano, H., Liu, J., Huang, P., and Lee, C. (2002). The circadian gene *Period2* plays an important role in tumor suppression and DNA damage response in vivo. *Cell* 111, 41–50.
- Hogenesch, J.B., Gu, Y.Z., Jain, S., and Bradfield, C.A. (1998). The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. *Proc. Natl. Acad. Sci. USA* 95, 5474–5479.

- Hughes, M.E., Hogenesch, J.B., and Kornacker, K. (2010). JTK_CYCLE: an efficient nonparametric algorithm for detecting rhythmic components in genome-scale data sets. *J. Biol. Rhythms* 25, 372–380.
- Kim, J.W., Gao, P., Liu, Y.C., Semenza, G.L., and Dang, C.V. (2007). Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. *Mol. Cell. Biol.* 27, 7381–7393.
- Kocak, H., Ackermann, S., Hero, B., Kahlert, Y., Oberthuer, A., Juraeva, D., Roels, F., Theissen, J., Westermann, F., Deubzer, H., et al. (2013). Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. *Cell Death Dis.* 4, e586.
- Kondratov, R.V., Shamanna, R.K., Kondratova, A.A., Gorbacheva, V.Y., and Antoch, M.P. (2006). Dual role of the CLOCK/BMAL1 circadian complex in transcriptional regulation. *FASEB J.* 20, 530–532.
- Kornmann, B., Schaad, O., Bujard, H., Takahashi, J.S., and Schibler, U. (2007). System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. *PLoS Biol.* 5, e34.
- Kourtidis, A., Jain, R., Carkner, R.D., Eifert, C., Brosnan, M.J., and Conklin, D.S. (2010). An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. *Cancer Res.* 70, 1783–1792.
- Lévi, F., Okyar, A., Dulong, S., Innominato, P.F., and Clairambault, J. (2010). Circadian timing in cancer treatments. *Annu. Rev. Pharmacol. Toxicol.* 50, 377–421.
- Littlewood, T.D., Hancock, D.C., Danielian, P.S., Parker, M.G., and Evan, G.I. (1995). A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. *Nucleic Acids Res.* 23, 1686–1690.
- Malynn, B.A., de Alboran, I.M., O'Hagan, R.C., Bronson, R., Davidson, L., DePinho, R.A., and Alt, F.W. (2000). N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. *Genes Dev.* 14, 1390–1399.
- Maris, J.M. (2010). Recent advances in neuroblastoma. *N. Engl. J. Med.* 362, 2202–2211.
- McDearmon, E.L., Patel, K.N., Ko, C.H., Walisser, J.A., Schook, A.C., Chong, J.L., Wilsbacher, L.D., Song, E.J., Hong, H.K., Bradfield, C.A., and Takahashi, J.S. (2006). Dissecting the functions of the mammalian clock protein BMAL1 by tissue-specific rescue in mice. *Science* 314, 1304–1308.
- Menssen, A., Hydrbring, P., Kapelle, K., Vervoorts, J., Diebold, J., Lüscher, B., Larsson, L.G., and Hermeking, H. (2012). The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. *Proc. Natl. Acad. Sci. USA* 109, E187–E196.
- Murphy, T.A., Dang, C.V., and Young, J.D. (2013). Isotopically nonstationary ¹³C flux analysis of Myc-induced metabolic reprogramming in B-cells. *Metab. Eng.* 15, 206–217.
- Preitner, N., Damiola, F., Lopez-Molina, L., Zakany, J., Duboule, D., Albrecht, U., and Schibler, U. (2002). The orphan nuclear receptor REV-ERB α controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* 110, 251–260.
- Pugh, T.J., Morozova, O., Attiyeh, E.F., Asgharzadeh, S., Wei, J.S., Auclair, D., Carter, S.L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013). The genetic landscape of high-risk neuroblastoma. *Nat. Genet.* 45, 279–284.
- Ramsey, K.M., Yoshino, J., Brace, C.S., Abrassart, D., Kobayashi, Y., Marcheva, B., Hong, H.K., Chong, J.L., Buhr, E.D., Lee, C., et al. (2009). Circadian clock feedback cycle through NAMPT-mediated NAD⁺ biosynthesis. *Science* 324, 651–654.
- Relógio, A., Westermarck, P.O., Wallach, T., Schellenberg, K., Kramer, A., and Herzog, H. (2011). Tuning the mammalian circadian clock: robust synergy of two loops. *PLoS Comput. Biol.* 7, e1002309.
- Sahar, S., and Sassone-Corsi, P. (2009). Metabolism and cancer: the circadian clock connection. *Nat. Rev. Cancer* 9, 886–896.
- Sahar, S., and Sassone-Corsi, P. (2012). Regulation of metabolism: the circadian clock dictates the time. *Trends Endocrinol. Metab.* 23, 1–8.
- Sato, T.K., Yamada, R.G., Ukai, H., Baggs, J.E., Miraglia, L.J., Kobayashi, T.J., Welsh, D.K., Kay, S.A., Ueda, H.R., and Hogenesch, J.B. (2006). Feedback repression is required for mammalian circadian clock function. *Nat. Genet.* 38, 312–319.
- Savvidis, C., and Koutsilieris, M. (2012). Circadian rhythm disruption in cancer biology. *Mol. Med.* 18, 1249–1260.
- Shachaf, C.M., Kopelman, A.M., Arvanitis, C., Karlsson, A., Beer, S., Mandl, S., Bachmann, M.H., Borowsky, A.D., Ruebner, B., Cardiff, R.D., et al. (2004). MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. *Nature* 431, 1112–1117.
- Shimomura, K., Kumar, V., Koike, N., Kim, T.K., Chong, J., Buhr, E.D., Whiteley, A.R., Low, S.S., Omura, C., Fenner, D., et al. (2013). Usp1, a suppressor of the circadian Clock mutant, reveals the nature of the DNA-binding of the CLOCK:BMAL1 complex in mice. *eLife* 2, e00426.
- Stringari, C., Wang, H., Geyfman, M., Crosignani, V., Kumar, V., Takahashi, J.S., Andersen, B., and Gratton, E. (2015). In vivo single-cell detection of metabolic oscillations in stem cells. *Cell Rep.* 10, 1–7.
- Taniguchi, H., Fernández, A.F., Setién, F., Roperio, S., Ballestar, E., Villanueva, A., Yamamoto, H., Imai, K., Shinomura, Y., and Esteller, M. (2009). Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. *Cancer Res.* 69, 8447–8454.
- Tokunaga, H., Takebayashi, Y., Utsunomiya, H., Akahira, J., Higashimoto, M., Mashiko, M., Ito, K., Niikura, H., Takenoshita, S., and Yaegashi, N. (2008). Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. *Acta Obstet. Gynecol. Scand.* 87, 1060–1070.
- Umemura, Y., Koike, N., Matsumoto, T., Yoo, S.H., Chen, Z., Yasuhara, N., Takahashi, J.S., and Yagita, K. (2014). Transcriptional program of Kpna2/Importin- α 2 regulates cellular differentiation-coupled circadian clock development in mammalian cells. *Proc. Natl. Acad. Sci. USA* 111, E5039–E5048.
- Ushmorov, A., Hogarty, M.D., Liu, X., Knauss, H., Debatin, K.M., and Beltinger, C. (2008). N-myc augments death and attenuates protective effects of Bcl-2 in tropically stressed neuroblastoma cells. *Oncogene* 27, 3424–3434.
- Valentijn, L.J., Koppen, A., van Asperen, R., Root, H.A., Haneveld, F., and Versteeg, R. (2005). Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. *Cancer Res.* 65, 3136–3145.
- Walz, S., Lorenzin, F., Morton, J., Wiese, K.E., von Eyss, B., Herold, S., Rycak, L., Dumay-Odelot, H., Karim, S., Bartkuhn, M., et al. (2014). Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. *Nature* 511, 483–487.
- Wang, Q., Diskin, S., Rappaport, E., Attiyeh, E., Mosse, Y., Shue, D., Seiser, E., Jagannathan, J., Shusterman, S., Bansal, M., et al. (2006). Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. *Cancer Res.* 66, 6050–6062.
- Weljie, A.M., Newton, J., Mercier, P., Carlson, E., and Slupsky, C.M. (2006). Targeted profiling: quantitative analysis of 1H NMR metabolomics data. *Anal. Chem.* 78, 4430–4442.
- Wolf, E., Lin, C.Y., Eilers, M., and Levens, D.L. (2015). Taming of the beast: shaping Myc-dependent amplification. *Trends Cell Biol.* 25, 241–248.
- Xiang, Y., Stine, Z.E., Xia, J., Lu, Y., O'Connor, R.S., Altman, B.J., Hsieh, A.L., Gouw, A.M., Thomas, A.G., Gao, P., et al. (2015). Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. *J. Clin. Invest.* 125, 2293–2306.
- Yeh, C.M., Shay, J., Zeng, T.C., Chou, J.L., Huang, T.H., Lai, H.C., and Chan, M.W. (2014). Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. *Int. J. Oncol.* 45, 2101–2107.
- Zhao, H., Zeng, Z.L., Yang, J., Jin, Y., Qiu, M.Z., Hu, X.Y., Han, J., Liu, K.Y., Liao, J.W., Xu, R.H., and Zou, Q.F. (2014). Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. *Int. J. Clin. Exp. Pathol.* 7, 619–630.